단일클론항체 항암제의 과민반응 = Hypersensitivity Reactions to Anticancer Monoclonal Antibodies

다국어 초록 (Multilingual Abstract)

Therapeutic monoclonal antibodies (TmAbs) are new treatment options for cancer.
While their use is more common, hypersensitivity reactions (HSRs) to these drugs have been increased, preventing the use of first-line therapies. The aim of this review is to update and discuss the HSRs to TmAbs in their clinical features and management. Type 1 hypersensitivity is the most common type of the HSRs to TmAbs, followed by cytokine release reactions (CRRs) and type 4 hypersensitivity.
Mixed reactions of various types might also occur. TmAbs can have different immunogenicity depending on their non-human epitope contents, target proteins, and solubilizing additives. It may be also affected by the patient’s baseline condition and the number of administrations. When HSRs occur, it is recommended to classify the mechanism into type 1/type 4 hypersensitivity and CRRs. A skin test and desensitization are generally the most useful management for type 1 hypersensitivity but there is no standardized protocol for TmAbs yet. Readministration is contraindicated in type 4 hypersensitivity reactions and supportive care is effective in CCRs.
Understanding the characteristics and measures for each HSRs may be helpful to ensure the safe use of anticancer monoclonal antibodies. (PeRM 2023;15:1-10)

참고문헌 (Reference)

1 이서영 ; 양민석 ; 정재우 ; 오미정 ; 박창한 ; 손성욱 ; 강혜련 ; 조영주 ; 대한천식알레르기학회 약물알레르기 워크그룹, "항암제 과민반응에 대한 탈감작요법의 최신지견" 대한 소아알레르기 호흡기학회 1 (1): 295-302, 2013

2 조민경 ; 문미라 ; 김현화 ; 강동윤 ; 이주연 ; 조상헌 ; 강혜련, "의약품부작용보고원시자료 기반 약물 아나필락시스 사례 분석" 대한 소아알레르기 호흡기학회 8 (8): 30-35, 2020

3 문일주 ; 박혜정 ; 김성렬 ; 고범석 ; 임동우 ; 박경희 ; 이재현 ; 박중원, "단일 3차 의료 기관의 약물 유발 아나필락시스 발생 현황" 대한내과학회 88 (88): 281-287, 2015

4 Perino E, "Xolair-induced recurrent anaphylaxis through sensitization to the excipient polysorbate" 120 : 664-666, 2018

5 Commins SP, "The relevance of tick bites to the production of IgE antibodies to the mammalian oligosaccharide galactose-α-1, 3-galactose" 127 : 1286-1293, 2011

6 Story SK, "Successful desensitization to brentuximab vedotin after hypersensitivity reaction" 13 : 749-751, 2014

7 O’Connell AE, "Successful desensitization to brentuximab vedotin after anaphylaxis" 14 : e73-e75, 2014

8 Minor DR, "Successful desensitization in a case of Stevens–Johnson syndrome due to vemurafenib" 22 : 410-411, 2012

9 Yamaguchi K, "Severe infusion reactions to cetuximab occur within 1 h in patients with metastatic colorectal cancer : results of a nationwide, multicenter, prospective registry study of 2126 patients in Japan" 44 : 541-546, 2014

10 김현화 ; 문미라 ; 조민경 ; 안경민 ; 정수지 ; 강동윤 ; 이서영 ; 조상헌 ; 강혜련, "Rituximab 과민반응 환자에서의 단일 농도 탈감작 프로토콜과 단계별 희석 탈감작 프로토콜의 비교" 대한 소아알레르기 호흡기학회 8 (8): 135-141, 2020

11 Fouda GE, "Rituximab Hypersensitivity : From clinical presentation to management" 11 : 572863-, 2020

12 Behrens EM, "Review : Cytokine storm syndrome : looking toward the precision medicine era" 69 : 1135-1143, 2017

13 Cook-Bruns N, "Retrospective analysis of the safety of Herceptin immunotherapy in metastatic breast cancer" 61 : 58-66, 2001

14 Siena S, "Reduced incidence of infusion-related reactions in metastatic colorectal cancer during treatment with cetuximab plus irinotecan with combined corticosteroid and antihistamine premedication" 116 : 1827-1837, 2010

15 Park J-W, "Recent change of the etiology of drug induced anaphylaxis in a Korean tertiary care hospital" 14 : 109-113, 2022

16 Zanotti KM, "Prevention and management of antineoplastic-induced hypersensitivity reactions" 24 : 767-779, 2001

17 González-de-Olano D, "Positive basophil activation test following anaphylaxis to pertuzumab and successful treatment with rapid desensitization" 4 : 338-340, 2016

18 Grillo-Lopez AJ, "Overview of the clinical development of rituximab : first monoclonal antibody approved for the treatment of lymphoma" 26 : 66-73, 1999

19 DeVita MD, "Multiple successful desensitizations to brentuximab vedotin : a case report and literature review" 12 : 465-471, 2014

20 Li G, "Monoclonal antibody-related drugs for cancer therapy" 7 : 178-184, 2013

21 George TJ, Jr, "Managing cetuximab hypersensitivity-infusion reactions : incidence, risk factors, prevention, and retreatment" 8 : 72-77, 2010

22 Barone G, "Managing adverse events associated with dinutuximab beta treatment in patients with high-risk neuroblastoma : Practical guidance" 23 : 537-548, 2021

23 Hong DI, "Indications, protocols, and outcomes of drug desensitizations for chemotherapy and monoclonal antibodies in adults and children" 2 : 13-19, 2014

24 Keating K, "Incidence of cetuximab-related infusion reactions in oncology patients treated at the University of North Carolina Cancer Hospital" 20 : 409-416, 2014

25 Baldo BA, "Immune- and non-immune-mediated adverse effects of monoclonal antibody therapy: a survey of 110 approved antibodies" 11 : 17-, 2022

26 Hong D, "Hypersensitivity to monoclonal antibodies used for cancer and inflammatory or connective tissue diseases" 123 : 35-41, 2019

27 Galvão VR, "Hypersensitivity to biological agents—updated diagnosis, management, and treatment" 3 : 175-185, 2015

28 Gutiérrez-Fernández D, "Hypersensitivity to alemtuzumab. A safe and effective desensitization protocol: A case report" 25 : 1016-1020, 2019

29 Isabwe GAC, "Hypersensitivity reactions to therapeutic monoclonal antibodies : Phenotypes and endotypes" 142 : 159-170, 2018

30 Brennan PJ, "Hypersensitivity reactions to mAbs : 105 desensitizations in 23patients, from evaluation to treatment" 124 : 1259-1266, 2009

31 Vega A, "Hypersensitivity reactions to cancer chemotherapy : Practical recommendations of ARADyAL for diagnosis and desensitization" 31 : 364-384, 2021

32 Askin Gülsen BW, "Hypersensitivity reactions to biologics(part II) : classifications and current diagnostic and treatment approaches" 29 : 139-154, 2020

33 Gulsen A, "Hypersensitivity reactions to biologics(part I) : allergy as an important differential diagnosis in complex immune-derived adverse events" 29 : 97-125, 2020

34 Akarsu A, "Hypersensitivity reactions to biologicals : from bench to bedside" 7 : 71-83, 2020

35 Vultaggio A, "Hypersensitivity reactions to biologic agents" 34 : 615-632, 2014

36 Labella M, "Hypersensitivity reactions and anaphylaxis to checkpoint inhibitor-monoclonal antibodies and desensitization" 126 : 623-629, 2021

37 Clark SL, "Histopathologic spectrum of hypersensitivity reactions associated with anti-CD52 therapy(alemtuzumab)" 43 : 989-993, 2016

38 O’Neil BH, "High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history" 25 : 3644-3648, 2007

39 Hanbali A, "Fatal hypersensitivity reaction to gemtuzumab ozogamicin associated with platelet transfusion" 64 : 1401-1402, 2007

40 Przepiorka D, "FDA approval : blinatumomab" 21 : 4035-4039, 2015

41 Gomes ER, "Epidemiology of hypersensitivity drug reactions" 5 : 309-316, 2005

42 Sobrero AF, "EPIC : phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer" 26 : 2311-2319, 2008

43 Bonamichi-Santos R, "Diagnoses and management of drug hypersensitivity and anaphylaxis in cancer and chronic inflammatory diseases : Reactions to taxanes and monoclonal antibodies" 54 : 375-385, 2018

44 Minister of Health and Welfare, "Detailed matters of criteria and methods for application of benefit (Medicine. Minister of Health and Welfare Notification No. 2022-77)"

45 Alvarez-Cuesta E, "Delving into cornerstones of hypersensitivity to antineoplastic and biological agents : value of diagnostic tools prior to desensitization" 70 : 784-794, 2015

46 Suntharalingam G, "Cytokine storm in a phase 1 trial of the anti-CD28monoclonal antibody TGN1412" 355 : 1018-1028, 2006

47 Shimabukuro-Vornhagen A, "Cytokine release syndrome" 6 : 56-, 2018

48 Freeman CL, "Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions" 126 : 2646-2649, 2015

49 Brown SGA, "Clinical features and severity grading of anaphylaxis" 114 : 371-376, 2004

50 Coombs RRA, "Clinical aspects of immunology" Blackwell Scientific Publications 317-337, 1963

51 Cunningham D, "Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer" 351 : 337-345, 2004

52 Beck SC, "Biomarkers in human anaphylaxis : A critical appraisal of current evidence and perspectives" 10 : 494-, 2019

53 Castells MC, "Anaphylaxis to chemotherapy and monoclonal antibodies" 35 : 335-348, 2015

54 Noguerado-Mellado B, "Anaphylactic shock due to brentuximab-vendotin confirmed by skin test and in vitro tests" 5 : 1427-1429, 2017

55 Kim HH, "Analysis of breakthrough reactions in 1, 143 desensitization procedures in a single tertiary hospital using a one-bag desensitization protocol" 3 : 786822-, 2022

56 Pichler WJ, "Adverse side-effects to biological agents" 61 : 912-920, 2006

57 Baldo B, "Adverse events to monoclonal antibodies used for cancer therapy : Focus on hypersensitivity responses" 2 : e26333-, 2013